IchthysTrades
$OCUL Don't let the algorithmic bot headlines distract you from the biggest breaking development in this morning's update:
1. SOL-X is officially moving to 48-WEEK dosing (once a year). This was not on the market's radar. Management upgraded the protocol from 6 months to annual maintenance based on the extended durability demonstrated in SOL-1. AXPAXLI is no longer being pitched just to match standard anti-VEGF intervals—it is positioning to become an annual maintenance monopoly.
2. Added Dr. Riad Sherif to the Board of Directors. Current CEO of Oculis with former senior leadership at Sanofi, Novartis, and Alcon.
3. IMO, The pipeline’s commercial ceiling and the takeover floor just moved higher. Know what you hold. 🎯💎
1
13
